Effect of chloroquine phosphate treatment on serum MMP-9 and TIMP-1 levels in patients with systemic lupus erythematosus

Abstract

Antimalarials are widely used for the treatment of systemic lupus erythematosus. However, their mechanisms of action have not been fully elucidated. Literature data indicate that matrix metalloproteinases may play a role in the immune response and tissue damage that occur in autoimmune skin diseases. The aim of this study was to determine the effect of 3 months of chloroquine treatment on serum levels of MMP-9 and TIMP-1 in patients with systemic lupus erythematosus. The study group consisted of 25 patients with systemic lupus erythematosus and 25 sex- and age-matched healthy volunteers. Before drug administration, serum levels of MMP-9 and TIMP-1 were determined by enzyme-linked immunosorbent assay. The same procedure was performed after chloroquine treatment. We found significantly higher median serum levels of MMP-9 in patients with systemic lupus erythematosus before therapy (57.20 ng/ml) when compared with controls (44.50 ng/ml) (p < 0.001). After chloroquine therapy the median MMP-9 serum level of systemic lupus erythematosus patients decreased significantly (43 ng/ml; p < 0.001). Before treatment the median TIMP-1 serum level in the patients with systemic lupus erythematosus was significantly higher than in the control group (500 vs. 200 ng/ml; p < 0.001), and after therapy it increased significantly (750 ng/ml TIMP-1; p < 0.001). The results suggest that chloroquine treatment may affect the matrix metalloproteinase network, and this effect may contribute to the immunoregulatory and anti-inflammatory properties of antimalarials.

Keywords

antimalarials metalloproteinases systemic lupus erythematosus

References

Steinberg AD Concepts of pathogenesis of systemic lupus erythematosus . Clin Immunol Immunopathol 1992; 63: 19-22.

Harley JB , Kelly JA Genetic basis of systemic lupus erythematosus: a review of the unique genetic contributions in African Americans. J Natl Med Assoc 2002; 94: 670-677.

Herrmann M. , Voll RE , Kalden JR Etiopathogenesis of systemic lupus erythematosus. Immunol Today 2000; 21: 424-426.

Sarzi-Puttini P. , Atzeni F. , Iaccarino L. , Doria A. Environment and systemic lupus erythematosus: an overview. Autoimmunity 2005; 38: 465-472.

Hess DC Cerebral lupus vasculopathy. Mechanisms and clinical relevance. Ann N Y Acad Sci 1997; 823: 154-168.

Ritschel WA , Hammer GV , Thompson GA Pharmakinetics of antimalarials and proposals for dosage regiments. Int J Clin Pharmacol Biopharm 1978; 16: 395-401.

Laaksonem AL , Koskiahde V. , Juva K. Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. Scad J Rheumatol 1974; 3: 103-108.

McChesney EW , Rothfield NF Comparative metabolic studies of chloroquine and hydroxychloroquine. Arthritis Rheum 1964 ; 7: 328-329.

Zidovetzki R. , Sherman IW , Cardenas M. , Borchardt DB Chloroquine stabilization of phospholipid membranes against diacetylglycero-induced perturbation. Biochem Pharmacol 1993; 45: 183-189.

10.

Salmeron G. , Lipsky PE Immunosuppressive potentials of antimalarials . Am J Med 1983; 75: 19-24.

11.

Sjölin-Forsberg G. , Lindstrom B. , Berne B. Topical chloroquine applied before irradiation protects against ultraviolet B (UVB)-and UVA-induced erythema but not against immediate pigment darkening. Photodermatol Photoimmunol Photomed 1992/1993; 9: 220-224.

12.

Fox R. Antimalarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus 1996 ; 5: 4-10.

13.

Fox RI , Kang HI Mechanism of action of antimalarials drugs: inhibition of antigen processing and presentation. Lupus 1993; 2: S9-S12.

14.

Wozniacka A. , Carter A. , McCauliffe DP Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit. Lupus 2002 ; 11: 71-81.

15.

Yi AK , Peckham DW , Ashman RF , Krieg A. CpG DNA rescues B cells from apoptosis by activating NFkappaB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway . Int Immunol 1999; 11: 2015-2024.

16.

Coban C. , Ishii KJ , Kawai T. , et al. Toll-like receptor 9 mediates innate immune activation by the malaria pigment hemozoin. J Exp Med 2005; 201: 19-25.

17.

Lenert P.

Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases?

Clin Exp Immunol 2005; 140: 1-10.

18.

Opdenakker G. , Van den Steen PE , Dubois B. , et al. Gelatinase B functions as a regulator and effector in leukocyte biology. J Leukoc Biol 2001; 69: 851-859.

19.

Chakraborti S. , Mandal M. , Das S. , Mandal A. , Chakraborti T. Regulation of matrix metalloproteinasses: an overview. Mol Cell Biochem 2003; 253: 269-285.

20.

Munoz-Valle JF , Vázquez-Del Mercado M. , García-Iglesias T. , et al. T(H)1/T(H)2 cytokine profile, metalloprotease-9 activity and hormonal status in pregnant rheumatoid arthritis and systemic lupus erythematosus patients . Clin Exp Immunol 2003; 131: 377-384.

21.

Hornebeck W. Down-regulation of tissue inhibitor of matrix metalloprotease-1 (TIMP-1) in aged human skin contributes to matrix degeneration and impaired cell growth and survival. Pathol Biol 2003; 51: 569-573.

22.

Baker AH , Edwards DR , Murphy G. Metalloproteinase inhibitors: biological actions and therapeutic opportunities . J Cell Sci 2002; 115: 3719-3727.

23.

Woessner JF Jr. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991 ; 5: 2145-2154.

24.

Robak E. , Wierzbowska A. , Chmiela M. , Kulczycka L. , Sysa-Jedrzejowska, Robak T. Circulating total and active metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in patients with systemic lupus erythematosus. Mediators Inflamm 2006; 2006(1): 17898.

25.

Makowski GS , Ramsby ML Concentrations of circulating matrix metalloproteinase 9 inversely correlate with autoimmune antibodies to double stranded DNA: implications for monitoring disease activity in systemic lupus erythematosus. Mol Pathol 2003; 56: 244-247.

26.

Mawrin C. , Brunn A. , Rocken C. , Schroder JM Peripheral neuropathy in systemic lupus erythematosus: pathomorphological features and distribution pattern of matrix metalloproteinases. Acta Neuropathol 2003; 105: 365-372.

27.

Zucker S. , Mian N. , Drews M. , et al. Increased serum stromelysin-1 levels in systemic lupus erythematosus: lack of correlation with disease activity. J Rheumatol 1999; 26: 78-80.

28.

Faber-Elmann A. , Sthoeger Z. , Tcherniack A. , Dayan M. , Mozes E. Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin Exp Immunol 2002; 127: 393-398.

29.

Toubi E. , Kessel A. , Grushko G. , Sabo E. , Rozenbaum M. , Rosner I. The association of serum matrix metalloproteinases and their tissue inhibitor levels with scleroderma disease severity. Clin Exp Rheumatol 2002; 20: 221-224.

30.

Stuhlmeier KM Mepacrine inhibits matrix metalloproteinases-1 (MMP-1) and MMP-9 activation in human fibroblast-like synoviocytes. J Rheumatol 2003; 30: 2330-2337.

31.

Stuhlmeier KM , Pollaschek C. Quinacrine but not chloroquine inhibits PMA-induced upregulation of matrix metalloproteinases in leukocytes: quinacrine acts at the transcriptional level through a PLA2-independent mechanism. J Rheumatol 2006; 33: 472-480.

32.

Hochberg MC Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.

33.

Liang MH , Socher SA , Larson MG , Schur PH Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989; 32: 1107-1118.

34.

Liu Y. , Zheng M. , Yin WH , Zhang B. Relationship of serum levels of HGF and MMP-9 with disease activity of patients with systemic lupus erythematosus. Zhejiang Da Xue Xue Bao Yi Xue Ban 2004; 33: 340-343.

35.

Matache C. , Stefanescu M. , Dragomir C. , et al. Matrix metalloproteinase-9 and its natural inhibitor TIMP-1 expressed or secreted by peripheral blood mononuclear cells from patients with systemic lupus erythematosus. J Autoimmun 2003; 20: 323-331.

36.

Wallace DJ Antimalarials: the real advance in lupus. Lupus 2001; 10: 385-387.

37.

Wozniacka A. , Lesiak A. , Narbutt J. , McCauliffe DP , Sysa-Jedrzejowska A. Chloroquine treatment influences proinflammatory cytokine levels in SLE patients . Lupus 2006; 15: 268-275.

38.

Wozniacka A. , Lesiak A. , Narbutt J. , Kobos J. , Pavel S. , Sysa-Jedrzejowska A. Chloroquine treatment reduces the number of cutaneous HLA-DR+ and CD1a+ cells in patients with systemic lupus erythematosus. Lupus 2007; 16: 89-94.

39.

Lim EJ , Lee SH , Lee JG , et al. Activation of toll-like receptor-9 induces matrix metalloproteinase-9 expression through Akt and tumor necrosis factor-alpha signaling. FEBS Lett 2006; 580: 4533-4538.

40.

Lim EJ , Lee SH , Lee JG , et al. Toll-like receptor 9 dependent activation of MAPK and NF-κB is required for the CpG ODN-induced matrix metalloproteinase-9 expression . Exp Mol Med 2007; 39: 239-245.

41.

Merrell MA , Ilvesaro JM , Lehtonen N. , et al. Toll-like receptor 9 agonists promote cellular invasion by increasing matrix metalloproteinase activity. Mol Cancer Res 2006; 4: 437-447.